Senseonics Holdings, Inc. SENS recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its ...

The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system As the first fully implantable device in the category, ...

Credit: Ascensia Diabetes Care. Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management. The FDA has designated the Eversense 365 ...

“When AID systems are used in conjunction with real-time CGM, people with diabetes experience more time in range, fewer incidences of hypoglycemia and greater peace of mind,” said Dr. Nicholas Argento ...

Senseonics Holdings SENS shares soared 5.3% in the last trading session to close at $7.33. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients using a lancet ...

Dr Anne Peters discusses updates in the ADA 2026 Standards of Care in Diabetes, focusing on the use of technology.

Please provide your email address to receive an email when new articles are posted on . The Tandem Mobi automated insulin delivery system can be integrated with ...

With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The ...